Karyopharm Therapeutics Inc. (KPTI) News
Filter KPTI News Items
KPTI News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
KPTI News Highlights
- For KPTI, its 30 day story count is now at 4.
- Over the past 23 days, the trend for KPTI's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
- RYAN are the most mentioned tickers in articles about KPTI.
Latest KPTI News From Around the Web
Below are the latest news stories about KARYOPHARM THERAPEUTICS INC that investors may wish to consider to help them evaluate KPTI as an investment opportunity.
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 44,600 restricted stock units (RSUs) to eight newly-hired employees. These RSU awards were granted as of May 31, 2023 pursuant to the Company's 2022 Inducement Stock Incentive Plan, as amended, as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 56 |
Karyopharm to Participate at the Jefferies Healthcare ConferenceKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the Jefferies Healthcare Conference in a fireside chat on Thursday, June 8, 2023 at 10:00 a.m. ET in New York, NY. |
Karyopharm to Present New Selinexor Data at the 2023 American Society of Clinical Oncology and European Hematology Association Annual MeetingsKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that several abstracts detailing new selinexor data have been selected to be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, being held June 2-6 in Chicago, Illinois and the 2023 European Hematology Association (EHA) Hybrid Congress, being held June 8-11 in Frankfurt, Germany. |
Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q1 2023 Earnings Call TranscriptKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Q1 2023 Earnings Call Transcript May 6, 2023 Operator: Good morning. My name is Ryan, and I will be your conference operator today. At this time, I would like to welcome everyone to the Karyopharm Therapeutics First Quarter 2023 Financial Results Conference Call. [Operator Instructions] Please be advised that this call […] |
Karyopharm Therapeutics First Quarter 2023 Earnings: Beats ExpectationsKaryopharm Therapeutics ( NASDAQ:KPTI ) First Quarter 2023 Results Key Financial Results Revenue: US$38.7m (down 19... |
Why Karyopharm Therapeutics Shares Slumped ThursdayPresident and CEO Richard Paulson explained the lower revenue on the first-quarter earnings call by citing more competition; a greater utilization by patients of the company's Patient Assistance Program, including Medicare patients without sufficient funding; and a higher gross to net ratio from increased Medicare rebates and 340B discounts, year over year. The big problem for investors, though, was the revenue drop was combined with downgraded guidance. The company said it now expects annual revenue between $145 million and $160 million, compared to earlier guidance of between $160 million and $175 million. |
Karyopharm Therapeutics (KPTI) Q1 2023 Earnings Call TranscriptAt this time, I would like to welcome everyone to the Karyopharm Therapeutics first quarter 2023 financial results conference call. Thank you, operator, and thank you all for joining us on today's conference call to discuss Karyopharm's first quarter 2023 financial results and recent company progress. For today's call, as seen on Slide 2, I'm joined by Richard, Sohanya, Reshma, and Mike, who will provide an update on our Q1 results and recent clinical developments. |
Karyopharm Therapeutics (KPTI) Reports Q1 Loss, Tops Revenue EstimatesKaryopharm Therapeutics (KPTI) delivered earnings and revenue surprises of 11.76% and 2.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock? |
Karyopharm Reports First Quarter 2023 Financial Results and Highlights Recent Company ProgressKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today reported financial results for the quarter ended March 31, 2023. In addition, Karyopharm highlighted select corporate milestones and provided an overview of its key clinical development programs. |
Karyopharm Announces Presentation of Interim Data from Phase 2 Study of Single-Agent Eltanexor in Relapsed/Refractory (R/R) Higher-Risk Myelodysplastic Neoplasms (MDS) at 17th International Congress on MDSKaryopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced interim data from the Phase 2 portion of the open-label Phase 1/2 study of single-agent eltanexor in patients with higher R/R myelodysplastic neoplasms. The data, featured in a poster presentation at the 17th International Congress on Myelodysplastic Syndromes, showed that eltanexor has promising single-agent efficacy with a generally manageable safety profile |